Peuranpää P, et al. - Researchers examined the risk for early pregnancy loss in IVF/ICSI with a fresh or frozen-thawed embryo transfer (ET) in correlation with low (< 1.0 μg/L) or moderately low (1.0–1.9 μg/L) serum anti-Müllerian hormone (AMH) level. They conducted a retrospective cohort study on 1,383 women who had undergone their first oocyte retrieval for IVF/ICSI in Helsinki University Hospital in Helsinki, Finland, between 2012 and 2016, with all associated fresh (n = 1,315) and frozen-thawed (n = 1,418) ET cycles finished by August 2018. Measurement of AMH within 12 months before the IVF/ICSI stimulation revealed low AMH (<1.0 μg/L) in 235 (17.0%) women, moderately low AMH (1.0–1.9 μg/L) in 278 (20.1%) women and normal AMH (≥2.0 μg/L) in 870 (62.9%) women. Among 1,123 pregnancies, non-visualized pregnancy loss occurred in 285 (25.4%) and miscarriage occurred in 143 (12.7%). Outcomes suggest no correlation of a low or moderately low serum AMH level with miscarriage, non-visualized pregnancy loss or overall early pregnancy loss rate in the IVF/ICSI treatment.